Company Information
USD
2.85
- (-5.3%)
NASDAQ:TCRT, ALAUNOS THERAPEUTICS INC
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.
Address
8030 El Rio Street
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Ferdinand Groenewald
Vice President, Divisional
Mr. Dale Curtis Hogue, Jr
CEO/Director
Dr. Robert J Hofmeister, PhD
Director
Mr. Jaime Vieser
Director
Mr. Holger Weis
Director
Mr. Robert W. Postma
Director
Mr. Abhishek K Srivastava
Vice President, Divisional
Mr. Raffaele Baffa
Chief Medical Officer
Ownership
Institution Holdings
Discovery Capital Management LLC
15,461,829 (6.426%)
MSD Partners, L.P.
15,151,516 (6.297%)
Vanguard Group Inc
9,438,762 (3.923%)
Vanguard Investments Australia Ltd
6,058,962 (2.518%)
BlackRock Inc
4,970,232 (2.066%)
Geode Capital Management, LLC
2,163,473 (0.899%)
Fidelity Management & Research Company LLC
2,061,035 (0.857%)
State Street Corporation
757,826 (0.315%)
Advisor Group Holdings, Inc.
630,945 (0.262%)
BlackRock
551,916 (0.229%)
Individual Holdings
Mr. Robert W. Postma
1,241,870 (8.617%)
Mr. Jaime Vieser
745,321 (5.172%)
Mr. Holger Weis
160,167 (1.113%)
Mr. Abhishek K Srivastava
1,200 (0.008%)
Funds Holdings
Vanguard US Total Market Shares ETF
6,058,962 (2.518%)
BlackRock Extended Equity Market
447,992 (0.186%)
NT Ext Equity Mkt Idx Fd - DC - NL
130,903 (0.054%)
BlackRock U.S. Equity Market
103,924 (0.043%)
Extended Equity Market Fund M
55,393 (0.023%)
SSgA U.S. Total Market Index Fund
32,225 (0.013%)
BNYM Mellon SL Market Completion Fund
14,758 (0.006%)
NT Ext Equity Mkt Indx Fd DC Lending
5,270 (0.002%)
China Universal NASDAQ Bio-Tch ETF(QDII)
3,154 (0.001%)
Make Smart Investment Choices